NEW YORK, Jan. 28, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today the appointment of Dr. David Altarac as Vice President, Regulatory Affairs. In this position, Dr. Altarac will lead NeoStem's regulatory affairs operations as it grows in connection with the Company's therapeutic pipeline expansion in 2014 and beyond.
NeoStem is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by replacing and repairing damaged tissue, cells and organs and restoring their functionality to normal. The development of novel and proprietary cell therapy products is built around a robust intellectual property portfolio, and also utilizes the deep experience as well as engineering and innovation solutions of NeoStem's subsidiary, Progenitor Cell Therapy ("PCT"), a premier contract development and manufacturing organization that is a pioneer in the cell therapy industry, NeoStem continues to expand its clinical team. In August, Dr. Douglas W. Losordo, a leader in cell therapy and a cardiologist regarded for his career-long efforts to develop novel therapeutics, joined the Company as its Chief Medical Officer. As Vice President, Clinical Development and New Technologies, Dr. Jonathan Sackner-Bernstein will continue to oversee the Company's clinical development programs and his role will expand to include evaluation of opportunities to acquire or develop new technologies.
"Dr. Altarac brings to the Company an impressive resume of experience in U.S. and global regulatory affairs, operations, labeling and organizational design and we are thrilled to have his expertise as we expand our clinical development team," commented Dr. Douglas Losordo.Dr. Altarac comes to NeoStem after a successful 13 year tenure at Merck and Company, Inc. where he most recently held the position of Vice President, Regulatory Affairs Emerging Markets R & D at Merck Research Labs. In that position he was responsible for overseeing the regulatory affairs (operations and strategy) for Merck's Emerging Markets ("EM") group, which originally was comprised of Brazil, Russia, India, China, Korea, Turkey, and Mexico. One of his first efforts in that position was the integration of the Most of World regulatory organization into the company's EM Regulatory team to form a collaborative, global R & D regulatory organization with more than 325 staff operating in over 125 countries. He also worked to develop robust interfaces with regulatory support teams throughout Merck's business units including Worldwide Product Labeling, Global Regulatory Operations, Global Safety, and Merck Enterprise groups including Global Human Health, Merck Manufacturing Division, Merck Consumer Care and Merck Vaccines Division.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV